This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by French, J. Articles by Donehower, L. A. Search for Related Content PubMed PubMed Citation Articles by French, J. Articles by Donehower, L. A. Social Bookmarking                         What's this?

The Nature of the Heterozygous Trp53 Knockout Model for Identifi cation of Mutagenic Carcinogens

National Institute of Environmental Health Sciences, NIH, Research Triangle Park, North Carolina

Richard D. Storer

Merck Research Laboratories, West Point, Pennsylvania

Lawrence A. Donehower

Baylor College of Medicine, Houston, Texas

The heterozygous Trp 53 null allele C57BL/6 (N5) mouse is susceptible to the rapid development of neoplasia by mutagenic carcinogens relative to control strains. This mouse model of chemical carcinogenesis demonstrates 1) dose-related rapid induction of tumors (26 wks), 2) multiple sites of carcinogen-specifi c tissue susceptibility, and 3) carcinogen-induced loss of heterozygosity involving the Trp53 wild-type allele or a p53 haploinsufficiency permitting mutation of other critical protooncogenes and/or inactivation of tumor suppressor genes driving tumorigenesis. Demonstration of mutation or loss ofheterozygosity involving the Trp53 locus is consistent with a common finding in human cancers and supports extrapolation between rodents and humans. Using diverse experimental protocols, almost all mutagenic rodent carcinogens (including all mutagens that are carcinogenic to humans), but not nonmutagenic rodent carcinogens, induce tumors within 26 weeks of continuous exposure. These characteristics and results indicate that the mouse heterozygous for the Trp53 null allele may be of significant use for the prospective identification of mutagenic carcinogens of potential risk to human health.

Key Words: p53 haploinsufficiency • risk assessment • C57BL/6 (N5) mouse • loss of heterozygosity.

References

• el-Deiry WS (1998). Regulation of p53 downstream genes. Semin Cancer Biol 8(5): 345—357.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Prives C., Hall PA ( 1999). The p53 pathway. J Pathol 187(1): 112—126.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Donehower LA, Harvey M., Slagle BL, McArthur MJ, Montgomery CAJ, Butel JS, Bradley A. (1992). Mice defi cient for p53 are developmentally normal but susceptible to sponetaneous tumors. Nature 356(6366): 215— 221.
• Harvey M., McArthur MJ,Montgomery CAJ, Butel JS, Bradley A., Donehower LA (1993). Spontaneous and carcinogen-induced tumorigenesis in p53-defi cient mice. Nat Genet 5(3): 225—229.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Haseman JK, Elwell MR (1996). Evaluation of false positive and false negative outcomes in NTP long-term rodent carcinogenicity studies. Risk Anal 16(6): 813—820.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Karstadt M., Haseman JK (1997). Effect of discounting certain tumor types/sites on evaluations of carcinogenicity in laboratory animals. Am J Ind Med 31(5): 485—494.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Greenblatt MS, Bennett WP, Hollstein M., Harris CC (1994). Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 54(18): 4855—4878.[Free Full Text]
• Hollstein M., Sidransky D., Vogelstein B., Harris CC (1991). p53 mutations in human cancers. Science 253(5015): 49—53.[Abstract/Free Full Text]
• Weinberg RA (1991). Tumor suppressor genes. Science 254(5035): 1138— 1146.[Abstract/Free Full Text]
• Knudson, AG Jr Hethcote HW, Brown BW (1975). Mutation and childhood cancer: A probabilistic model for the incidence of retinoblastoma. Proc Natl Acad Sci USA 72(12): 5116—5120.[Abstract/Free Full Text]
• Knudson AG (1996). Hereditary cancer: Two hits revisited. J Cancer Res Clin Oncol 122(3): 135—140.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Venkatachalam S., Shi YP, Jones SN, Vogel H., Bradley A., Pinkel D., Donehower LA (1998). Retention of wild-type p53 in tumors from p53 heterozygous mice: Reduction of p53 dosage can promote cancer formation. Embo J 17(16): 4657—4667.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• French JE, Lacks GD, Trempus C., Dunnick JK, Mahler J., Tice RR, Tennant RW (2001). Loss of heterozygosity frequency at the Trp53 locus in p53 heterozygous ( + / - ) mice is carcinogen and tissue dependent. Carcinogenesis 21(1): 101—108.[CrossRef][Web of Science]
• Tennant RW, French JE, Spalding JW (1995). Identifying chemical carcinogens and assessing potential risk in short-term bioassays using transgenic mouse models. Environ Health Perspect 103(10): 942—950.[Web of Science][Medline] [Order article via Infotrieve]
• Tennant RW, Spalding J., French JE (1996). Evaluation of transgenic mouse bioassays for identifying carcinogens and noncarcinogens. Mutation Res 365:119—127.[Medline] [Order article via Infotrieve]
• Kemp CJ, Donehower LA, Bradley A., Balmain A. (1993). Reduction of p53 gene dosage does not increase intitiation or promotion but enhances malignant progression of chemically induced skin tumors. Cell 74(5): 813— 822.
• Kemp CJ, WheldonT, Balmain A (1994). p53-defi cient mice are extremely susceptible to radiation-induced tumorigenesis. Nature Gen 8: 66—69.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Eastin WC, Haseman JK, Mahler JF, Bucher JR (1998). The National Toxicology Program evaluation of genetically altered mice as predictive models for identifying carcinogens. Toxicol Pathol 26(4): 461—473.[Abstract/Free Full Text]
• Ohyama K., Chung CH, Chen E., Gibson CW, Misof K., Fratzl P., Shapiro IM (1997). p53 infl uences mice skeletal development. J Craniofac Gen Dev Biol 17(4): 161—171.[Web of Science][Medline] [Order article via Infotrieve]
• Armstrong JF, Kaufman MH, Harrison DJ, Clarke AR (1995). Highfrequency developmental abnormalities in p53-deficient mice. Curr Biol 5(8): 931—936.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Sah VP, Attardi LD, Mulligan GJ, Williams BO, Bronson RT, Jacks T. (1995). A subset of p53-defi cient embryos exhibit exencephaly. Nat Gen 10(2): 175—180.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Silver LM (1995). Mouse genetics: Concepts and applications. New York: Oxford University Press. p 362.
• Hulla J., French J., Dunnick J. (2001). Chromosome 11 allelotypes refl ect mechanism of chemical carcinogenesis in heterozygous p53-deficient mice. Carcinogenesis 21(1): 109—117.
• Hulla JE, French JE, Dunnick JK (2001). Chromosome 11 loss from thymic lymphomas induced in heterozygous Trp53 mice by phenolphthalein. Toxicol Sci 60(2): 264—270.[Abstract/Free Full Text]
• Bult CJ, Krupke DM, Sundberg JP, Eppig JT (2000). Mouse tumor biology database (MTB): Enhancements and current status. NucleicAcidsRes 28(1): 112—114.[Abstract/Free Full Text]
• Harvey M., McArthur MJ, Montgomery CAJ, Bradley A., Donehower LA (1993). Genetic background alters the spectrum of tumors that develop in p53-deficient mice. FASEB J 7(10): 938—943.[Abstract]
• Donehower LA, Harvey M., Vogel H., McArthur MJ, Montgomery CJ, Park SH, Thompson T., Ford RJ, Bradley A. (1995). Effects of genetic background on tumorigenesis in p53-defi cient mice. Mol Carcinog 14(1): 16— 22.
• Tennant RW, Stasiewicz S., Mennear J., French JE, Spalding JW (1999). Genetically altered mouse models for identifying carcinogens. IARC Sci Publ (146): 123—150.
• Spalding JW, French JE, Stasiewicz S., Furedi-Machacek M., Conner F., Tice RR, Tennant RW (2000). Responses of transgenic mouse lines p53( + / - ) and Tg.AC to agents tested in conventional carcinogenicity bioassays. Toxicol Sci 53(2): 213—223.[Abstract/Free Full Text]
• Mahler JF, Flagler ND, Malarkey DE, Mann PC, Haseman JK, Eastin W. (1998). Spontaneous and chemically induced proliferative lesions in Tg.AC transgenic and p53-heterozygous mice. Toxicol Pathol 26(4): 501— 511.
• Mahler JF (2000). The use of genetically altered animals in toxicology. Toxicol Pathol 28(3): 447—449.[Free Full Text]
• Tennant RW (1993). Stratification of rodent carcinogenicity bioassay results to refl ect relative human hazard. Mutat Res 286(1): 111—118.[Web of Science][Medline] [Order article via Infotrieve]
• Donehower LA (1996). The p53-deficient mouse: A model for basic and applied cancer studies. Semin Cancer Biol 7(5): 269—278.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Donehower LA, Godley LA, Aldaz CM, Pyle R., Shi YP, Pinkel D., Gray J., Bradley A., Medina D., Varmus HE (1996). The role of p53 loss in genomic instability and tumor progression in a murine mammary cancer model. Prog Clin Biol Res 395:1—11.[Web of Science][Medline] [Order article via Infotrieve]
• Venkatachalam S., Donehower LA (1998). Murinetumorsuppressormodels. Mutat Res 400(1—2): 391—407.[Web of Science][Medline] [Order article via Infotrieve]
• Stoll RE, Holden HE, Barthel CH, Blanchard KT (1999). Oxymetholone: III. Evaluation in the p53 + / - transgenic mouse model [comment] [see comments]. Toxicol Pathol 27(5): 513—518.[Abstract/Free Full Text]

Toxicologic Pathology, Vol. 29, No. 1 suppl, 24-29 (2001)
DOI: 10.1080/019262301753178456


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. J. Jonker, O. Bruning, M. van Iterson, M. M. Schaap, T. V. van der Hoeven, H. Vrieling, R. B. Beems, A. de Vries, H. van Steeg, T. M. Breit, et al. Finding transcriptomics biomarkers for in vivo identification of (non-)genotoxic carcinogens using wild-type and Xpa/p53 mutant mouse models Carcinogenesis, October 1, 2009; 30(10): 1805 - 1812. [Abstract] [Full Text] [PDF]

				M. J. Santostefano, D. J. Hoivik, and R. T. Miller Investigations of Clofibrate in Alternative Carcinogenicity Models International Journal of Toxicology, September 1, 2005; 24(5): 285 - 288. [Full Text] [PDF]

				C. E. Torrey, J. A. Campbell, D. J. Hoivik, R. T. Miller, J. S. Allen, P. C. Mann, K. Selinger, D. Rickert, P. M. Savina, and M. J. Santostefano Evaluation of the Carcinogenic Potential of Clofibrate in the p53+/- Mouse International Journal of Toxicology, September 1, 2005; 24(5): 289 - 299. [Abstract] [Full Text] [PDF]

				D. J. Hoivik, J. S. Allen, H. G. Wall, J. B. Nold, R. T. Miller, and M. J. Santostefano Studies Evaluating the Utility of N-Methyl-N-Nitrosourea as a Positive Control in Carcinogenicity Studies in the p53+/- Mouse International Journal of Toxicology, September 1, 2005; 24(5): 349 - 356. [Abstract] [Full Text] [PDF]

				J. M. Ward and D. E. Devor-Henneman Mouse Models of Human Familial Cancer Syndromes Toxicol Pathol, January 1, 2004; 32(1_suppl): 90 - 98. [Abstract] [PDF]

				Y. Matsuoka, K. Fukamachi, T. Hamaguchi, H. Toriyama-Baba, H. Kawaguchi, M. Kusunoki, H. Yoshida, and H. Tsuda Rapid Emergence of Mammary Preneoplastic and Malignant Lesions in Human c-Ha-ras Proto-Oncogene Transgenic Rats: Possible Application for Screening of Chemopreventive Agents Toxicol Pathol, October 1, 2003; 31(6): 632 - 637. [Abstract] [PDF]

				S. R. Payne and C. J. Kemp p27 Kip1 (Cdkn1b)-Deficient Mice Are Susceptible to Chemical Carcinogenesis and May Be a Useful Model for Carcinogen Screening Toxicol Pathol, June 1, 2003; 31(4): 355 - 363. [Abstract] [PDF]

				Committee on Carcinogenicity of Chemicals in Food, Consumer Products and the Environment Statement on ILSI/HESI Research Programme on Alternative Cancer Models Toxicol Pathol, February 1, 2003; 31(2): 254 - 257. [PDF]

This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by French, J. Articles by Donehower, L. A. Search for Related Content PubMed PubMed Citation Articles by French, J. Articles by Donehower, L. A. Social Bookmarking                         What's this?